Home
About
Overview
Sharing Data
ORCID
Help
History (29)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
p53 and Bcl-2 in small cell-lung cancer.
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.
See All 29 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.
Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol. 2014 Sep; 1(2):151-154.
View in:
PubMed
authors with profiles
Ravi Salgia
Seiko Diane Yamada